Sort
30,917 grants matching “tumor microenvironment”
Enhancing CAR-T cell therapy through theranostic targeted radionuclide therapy
$415,260Yanping Yang · Methodist Hospital Research Institute · R21 · FY2024 · CA
Role of type 2 immune response in pancreatic cancer tumorigenesis
$415,258Prasenjit Dey · Roswell Park Cancer Institute Corp · R01 · FY2022 · CA
Development of a pre-clinical syngeneic pig glioma model for research and translational studies
$415,257Robert C Rostomily · Methodist Hospital Research Institute · R21 · FY2024 · CA
TAM receptor inhibition in NF1-associated peripheral nerve sheath tumors
$415,205David W. Clapp · Indiana University Indianapolis · R01 · FY2025 · NS
TAM receptor inhibition in NF1-associated peripheral nerve sheath tumors
$415,205David W. Clapp · Indiana University Indianapolis · R01 · FY2022 · NS
Harnessing artificial microRNA clusters against glioblastoma epigenetic plasticity and resistance to therapy
$415,160Pier Paolo Peruzzi · Brigham And Women'S Hospital · R01 · FY2020 · NS
Harnessing Artificial MicroRNA Clusters Against Glioblastoma Epigenetic Plasticity and Resistance to Therapy
$415,160Pier Paolo Peruzzi · Brigham And Women'S Hospital · R01 · FY2025 · NS
Harnessing artificial microRNA clusters against glioblastoma epigenetic plasticity and resistance to therapy
$415,160Pier Paolo Peruzzi · Brigham And Women'S Hospital · R01 · FY2022 · NS
Harnessing Artificial MicroRNA Clusters Against Glioblastoma Epigenetic Plasticity and Resistance to Therapy
$415,160Pier Paolo Peruzzi · Brigham And Women'S Hospital · R01 · FY2023 · NS
Harnessing artificial microRNA clusters against glioblastoma epigenetic plasticity and resistance to therapy
$415,160Pier Paolo Peruzzi · Brigham And Women'S Hospital · R01 · FY2021 · NS
A First-in-Class FAP-activated Protoxin to disrupt the Tumor-Stroma Parasitic Cycle fueling lethal Prostate Cancer Progression
$415,155William Nathaniel Brennen · Johns Hopkins University · R01 · FY2025 · CA
A First-in-Class FAP-activated Protoxin to disrupt the Tumor-Stroma Parasitic Cycle fueling lethal Prostate Cancer Progression
$415,155William Nathaniel Brennen · Johns Hopkins University · R01 · FY2022 · CA
Extracellular DNA in regulation of multiple myeloma
$415,133Yulia Nefedova · Wistar Institute · R01 · FY2019 · CA
Identifying host factors that block engraftment and progression of transmissible cancer as a model of AML
$415,117Michael Jeffrey Metzger · Pacific Northwest Research Institute · R01 · FY2023 · CA
Radiation Therapy: Dissecting the Role of Stromal Cells in Tumor Control
$415,105David G Kirsch · Duke University · R01 · FY2013 · CA
Project 2: Cytoplasmic chromatin fragments (CCF) as a driver of liver cancer and target for intervention during aging
$415,067Peter D. Adams · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2022 · AG
Project 3 â Stromal derived IL-6/STAT3 signaling in the development and progression of PDAC
$415,057Michael C Ostrowski · Medical University Of South Carolina · P01 · FY2022 · CA
Transplanting Unique Human Microbiomes to Improve Immunotherapy in Glioblastoma
$415,031Braden Cox McFarland · University Of Alabama At Birmingham · R21 · FY2021 · CA
Inflammasomes - a driver of sexual dimorphism to glioma therapies
$414,953Vidyalakshmi Chandramohan · Duke University · R01 · FY2025 · NS
Notch function in postnatal intestinal and mesenteric lymphatics
$414,928Carrie J. Shawber · Columbia University Health Sciences · R01 · FY2017 · DK
A Multiplex Protein Biomarker-Based Immunoassay for the Early Detection of Bladder Cancer and its Implications in Tumor Biology
$414,870Charles J Rosser · Cedars-Sinai Medical Center · R01 · FY2024 · CA
Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the Golgi
$414,865Jonathan M Kurie · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Cell-Matrix Interactions and Migration
$414,817Kenneth Yamada · National Institute Of Dental & Craniofacial Research · ZIA · FY2022 · DE
ANTIBODY-TARGETED IMMUNOTHERAPY OF CANCER
$414,783Fox Chase Cancer Center · R01 · FY2002 · CA
Defining the contributions of Lyve-1 expressing macrophages to breast cancer growth and progression
$414,689Kathryn L Schwertfeger · University Of Minnesota · R01 · FY2025 · CA